A Randomized, Open-label, Active-Controlled, Parallel-Group, Exploratory Study on the Effects of Repeated Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Albiglutide (Primary) ; Exenatide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 06 Apr 2017 Status changed from recruiting to discontinued.
- 15 Mar 2017 Planned number of patients changed from 62 to 72.